ICON plc/$ICLR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About ICON plc

Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.

Ticker

$ICLR
Sector
Primary listing

Employees

39,900

Headquarters

Dublin, Ireland

ICON plc Metrics

BasicAdvanced
$15B
19.17
$9.73
1.20
-

What the Analysts think about ICON plc

Analyst ratings (Buy, Hold, Sell) for ICON plc stock.

Bulls say / Bears say

Adjusted earnings per share for Q2 2025 reached $3.26, beating analyst estimates of $3.19, which triggered a 14.6% jump in after-hours trading and signals solid earnings performance and investor optimism (Investing.com)
Gross business wins climbed 10.6% sequentially in Q2 to $2.97 billion, and net bookings generated a book-to-bill ratio of 1.02, highlighting strong contract flow and a growing backlog (Investing.com)
The board increased the share repurchase program by $500 million to $1.0 billion after buying back $250 million worth of shares at an average price of $146, indicating solid cash generation and a commitment to shareholder returns (Investing.com)
Quarterly revenue of $2.02 billion was down 4.8% versus Q2 2024, indicating ongoing top-line pressure even with quarter-on-quarter improvement (Investing.com)
Full-year 2025 revenue guidance has been narrowed to $7.85–$8.15 billion, below the previous $8.05–$8.65 billion forecast, causing an 8% share drop over concerns about slower growth (Investing.com)
Jefferies lowered ICON’s price target to $252 from $275, pointing to cautious biopharma spending among top clients and an uneven biotech recovery as persistent growth headwinds (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.

ICON plc Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ICON plc Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ICLR

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs